Literature DB >> 20009279

Indirect patient expenses for antituberculosis treatment in Tijuana, Mexico: is treatment really free?

Gema Yolanda Guzmán-Montes1, Renata Heras Ovalles, Rafael Laniado-Laborín.   

Abstract

BACKGROUND: One of the main problems faced by the Mexican National Tuberculosis Program is the high rate of patients abandoning treatment. This study aimed to determine the magnitude of unaccounted costs of tuberculosis (TB) treatment in Tijuana, Mexico.
METHODOLOGY: Subjects were recruited at 21 health centres. Patients had confirmed active pulmonary TB, had been on treatment for more than 12 weeks, and were aged 18 years and older. The questionnaire provided information about demographics, past and current episodes of TB, and various categories of expenses.
RESULTS: The study included 180 patients as follows: 48 had been diagnosed with tuberculosis in the past (26.6%) and had either currently relapsed or failed treatment; 160 (88.8%) were under directly observed therapy (DOT); 131 (72.8%) attended a health centre; and the rest received directly observed treatment at home. The daily cost of transportation to the health centre was MXN $25.88 +/- 3.22 (1 USD = 13 MXN). Thirty-two patients (17.8%) had to buy medication at least once, with a monthly medication expense of MXN $440.5 +/- 40.3. Patients receiving DOT at the health centre reported daily food and beverages expenses, spending MXN $56.5 +/- 10.1. Forty-two patients reported laboratory testing expenses, on average MXN $558.8 +/- 85.8 per month. Eighty patients (42.4%) reported expenses on radiographic/ultrasound studies, on average MXN $562.9 +/- 72.1 per six-month regimen. Conclusions TB diagnosis and treatment posed a significant economic burden on patients in terms of both cost and affordability; clinic-based DOT may contribute disproportionately to the costs incurred by patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20009279     DOI: 10.3855/jidc.489

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  6 in total

1.  HIV, drugs and the legal environment.

Authors:  Steffanie A Strathdee; Leo Beletsky; Thomas Kerr
Journal:  Int J Drug Policy       Date:  2014-09-16

2.  Comparative cost assessment of the Kato-Katz and FLOTAC techniques for soil-transmitted helminth diagnosis in epidemiological surveys.

Authors:  Benjamin Speich; Stefanie Knopp; Khalfan A Mohammed; I Simba Khamis; Laura Rinaldi; Giuseppe Cringoli; David Rollinson; Jürg Utzinger
Journal:  Parasit Vectors       Date:  2010-08-14       Impact factor: 3.876

Review 3.  Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.

Authors:  Yoko V Laurence; Ulla K Griffiths; Anna Vassall
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

4.  Multidrug-resistant tuberculosis patients' views of interventions to reduce treatment loss to follow-up.

Authors:  T Tupasi; A M C G Garfin; J M Mangan; R Orillaza-Chi; L C Naval; G I Balane; R Basilio; A Golubkov; E S Joson; W-J Lew; V Lofranco; M Mantala; S Pancho; J N Sarol; A Blumberg; D Burt; E V Kurbatova
Journal:  Int J Tuberc Lung Dis       Date:  2017-01-01       Impact factor: 2.373

5.  Measuring Catastrophic Costs Due to Tuberculosis in Myanmar.

Authors:  Si Thu Aung; Aung Thu; Htin Lin Aung; Min Thu
Journal:  Trop Med Infect Dis       Date:  2021-07-14

6.  Comparison of two cash transfer strategies to prevent catastrophic costs for poor tuberculosis-affected households in low- and middle-income countries: An economic modelling study.

Authors:  William E Rudgard; Carlton A Evans; Sedona Sweeney; Tom Wingfield; Knut Lönnroth; Draurio Barreira; Delia Boccia
Journal:  PLoS Med       Date:  2017-11-07       Impact factor: 11.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.